Basit öğe kaydını göster

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

dc.contributor.authorProot, Pieter
dc.contributor.authorDel Prato, Stefano
dc.contributor.authorPaldanius, Paivi M.
dc.contributor.authorChiang, YannTong
dc.contributor.authorStumvoll, Michael
dc.contributor.authorMatthews, David R.
dc.date.accessioned2021-03-06T07:16:03Z
dc.date.available2021-03-06T07:16:03Z
dc.date.issued2019
dc.identifier.citationMatthews D. R. , Paldanius P. M. , Proot P., Chiang Y., Stumvoll M., Del Prato S., "Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial", LANCET, cilt.394, ss.1519-1529, 2019
dc.identifier.issn0140-6736
dc.identifier.othervv_1032021
dc.identifier.otherav_dc12a928-0bdc-4e87-b77b-60fc5fa787da
dc.identifier.urihttp://hdl.handle.net/20.500.12627/145051
dc.identifier.urihttps://doi.org/10.1016/s0140-6736(19)32131-2
dc.description.abstractBackground Early treatment intensification leading to sustained good glycaemic control is essential to delay diabetic complications. Although initial combination therapy has been suggested to offer more opportunities than a traditional stepwise approach, its validity remains to be determined.
dc.language.isoeng
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.subjectTemel Tıp Bilimleri
dc.subjectFamily Practice
dc.subjectFundamentals and Skills
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleGlycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
dc.typeMakale
dc.relation.journalLANCET
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume394
dc.identifier.issue10208
dc.identifier.startpage1519
dc.identifier.endpage1529
dc.contributor.firstauthorID2505367


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster